Chronic Obstructive Pulmonary Disease, Asthma, or Both

Faculty

Sidney S. Braman, MD, FCCP (Moderator) 
Head, Chronic Obstructive Pulmonary Disease Care
Division of Pulmonary, Critical Care and Sleep Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Reynold A. Panettieri, Jr, MD
Robert L. Mayock and David A. Cooper Professor of Medicine
Director, Airways Biology Initiative
Adjunct Professor, Wistar Institute
Deputy Director, Center of Excellence in Environmental Toxicology
University of Pennsylvania Medical Center
Pulmonary, Allergy, & Critical Care Division
Translational Research Laboratories (TRL)
Philadelphia, Pennsylvania

James F. Donohue, MD
Professor of Medicine
Division Chief
Pulmonary Diseases and Critical Care Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Target Audience

The educational design of this activity addresses the needs of pulmonologists, allergists, primary care providers, and other clinicians involved in the diagnosis and ongoing management of patients with chronic airway limitations.

Statement of Need

As chronic inflammatory diseases associated with airflow obstruction, asthma and chronic obstructive pulmonary disease (COPD) share a number of signs of symptoms. It has recently been recommended that patients who exhibit clinical features of both asthma and COPD should receive a diagnosis of asthma-COPD overlap syndrome (ACOS). This Clinical Research Updates roundtable examines the etiology of ACOS, including pathophysiologic mechanisms that appear to contribute to the development of both asthma and COPD. The expert faculty panel examines best practices for the differential diagnosis of asthma and COPD, highlighting clinical presentations that suggest an ACOS diagnosis may be warranted. Recommendations for initial and long-term treatment of patients with chronic airway limitations are also discussed, including the evolving roles of biomarkers and the latest evidence for current and emerging biologic therapies.  

Learning Objectives

Upon completion of this activity, participants should be able to:

1. Compare the pathologic underpinnings and clinical characteristics of 3 diseases of chronic airflow limitation: asthma, COPD and ACOS
2. Differentially diagnose asthma, COPD, and ACOS based on medical history, clinical features, and appropriate ancillary testing
3. Individualize therapy for patients with disorders of chronic airflow limitation to address the underlying diagnosis, medical status, clinical profiles of available medication, and relevant comorbidities
4. Educate patients with asthma and/or COPD on lifestyle changes, therapeutic options, and the need to adhere to treatment regimens

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Education

Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-15-050-H01-P)

This is a knowledge based activity.

Instructions for Obtaining Credit

In order to receive credit, participants must complete the preactivity questionnaire, postactivity questionnaire, and program evaluation. Participants must also score at least a 70% on the posttest.

For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v8.0 or greater), Chrome, or Firefox

MAC
MAC OS 10+
Flash Player Plugin (v7.0.1.9 or greater)
Safari

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Sidney S. Braman, MD, FCCP (Moderator): Consultant (Boehringer Ingelheim, Meda Pharmaceuticals Inc., Teva Pharmaceutical Industries, Ltd., Forest Laboratories, Sunovion Pharmacetuicals Inc.); Speakers Bureau (Genentech Inc.)

Reynold A. Panettieri, Jr, MD:  Consultant (AstraZeneca, Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd.); Grant/Research (AstraZeneca, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., National Institutes of Health, Roche, sanofi-aventis U.S. LLC.)

James F. Donohue, MD: Consultant (AstraZeneca, Boehringer ingelheim, GlaxoSmithKline, Novartis Pharmaceuticals, Sunovion Pharmaceuticals Inc.) 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

• Rose O'Connor, PhD Nothing to disclose
• Ashley Marostica, RN, MSN Nothing to disclose
• Amanda Glazar, PhD Nothing to disclose
• Andrea Funk Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration (FDA). Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.